In a post hoc analysis of both composite outcomes (HF hospitalization or cardiovascular mortality), it was unclear whether SGLT2 offered benefit in patients who had undergone CRT [hazard ratio (HR) 0.85, 95% CI 0.53 to 1.36 and HR 0.89, 95% CI 0.46 to 1.68, respectively].11 Here, SLC5A2 is linked to hydrops fetalis.